The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer

The antiestrogen tamoxifen was examined for its effect on the interaction of monoclonal antibodies with the multidrug resistance markers: with Pgp and MRP1 in the cultured T-lymphoblast leukemia cell line Jurkat and with BCRP in the cultured cervical cancer cell line HeLa. The investigation used immunofluorescence and flow cytofluorimetric assays, primary monoclonal and isotypic antibodies labeled with the fluorescent dyes FITS and PE. After tamoxifen use, there was an increase in specific fluorescence and the number of specifically fluorescent cells on incubation with Pgp and BCRP antibodies and a reduction in those on incubation with MRP1 antibodies. This directly indicates that tomoxifen binds to Pgp, BCRP, and MRP1, which inevitably results in a decrease in the intracellular concentration of the antiestrogen available for the interaction with other cellular targets, including that with estrogen receptors. The authors consider that there is every reason to consider Pgp, BCRP, and MRP1 as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer with the positive estrogen receptor status.

tamoxifen, multidrug resistance proteins, Pgp, MRP1, BCRP, breast cancer, predictive markers

1. Rohlff C., Blagosklonny M.V., Kyle E. et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/ cip1). Prostate 1998;37(1):51–9.

2. Cheng A.L., Chuang S.E., Fine R.L. et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998;55(4):523–31.

3. Sharif T.R., Sharif M. A novel approach for examining the anti-proliferative effect of protein kinase C inhibitors against human astrocytoma cells. Int J Oncol 1998;13(4):685–92.

4. Lavie Y., Zhang Z.C., Cao H.T. et al. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 1998;77(6):928–32.

5. Chen T.C., Su S., Fry D., Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 2003;97(9):2363–73.

6. Ahn S.J., Yoon M.S., Hyuk S. et al. Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. J Cell Biochem 2003;89(3):520–8.

7. Isaac Y.K., Byung-Chul K., Do Hwan S. et al. Raloxifene, a mixed estrogen agonist/ antagonist, induces apoptosis in androgen- independent human prostate cancer cell lines. Cancer Res 2002;62:5365–9.

8. Fu Y.M., Li Q.M., Zhang .CY. et al. Effects of 40H-tamoxifen on the proliferation and apoptosis of prostate stromal cells. Zhonghua Nan Ke Xue 2007;13(7):620–3.

9. Lagadec C., Adriaenssens E., Toillon R.A. et al. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2008;27(10):1472–7.

10. Nazarewicz R.R., Zenebe W.J., Parihar A. et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthas. Cancer Res 2007;67(3):1282–90.

11. Nagahara Y., Shiina I., Nakata K.

12. et al. Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B. Cancer Sci 2008;99(3):608–14.

13. Kallio A., Zheng A., Dahllund J. et al. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10(6):1395–410.

14. Bursch W., Ellinger A., Kienzl H. et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996;17(8):1595–607.

15. Bursch W., Hochegger K., Torok L. et al. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 2000;113 (7):1189–98.

16. Bilir A., Altinoz M.A., Erkan M. et al. Autophagy and nuclear changes in FM3A breast tumor cells after

17. epirubicin, medroxyprogesterone and tamoxifen treatment in vitro. Pathobiology 2001;69(3):120–6.

18. Scarlatti F., Bauvy C., Ventruti A. et al. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 2004;279(18):18384–91.

19. Amaravadi R.K., Yu D., Lum J.J. et al. Autophagy inhibition enhances therapy- induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117(2):326–36.

20. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008;44(1):30–8.

21. O’Byrne K.J., Dalgleish A.G., Browning M.J. et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36(2):151–69.

22. Vainio H. Targeting angiogenesis — a novel mode in cancer chemoprevention. Asian Pac J Cancer Prev 2003;4(2):83–6.

23. Cáceres W., González S. Angiogenesis and cancer: recent advances. P R Health Sci J 2003; 22(2):149–51.

24. Gagliardi A.R., Hennig B., Collins D.C. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996;16(3):1101–6.

25. Butta A., MacLennan K., Flanders K.C. et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52(15):4261–4.

26. Garvin S., Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003;63:8742–8.

27. McGlynn L.M., Kirkegaard T., Edwards J. et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009;15(4):1487–95.

28. Frogne T., Jepsen J.S., Larsen S.S. et al. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005;12(3):599–614.

29. Zhou Y., Eppenberger-Castori S., Marx C. et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005;37(5):1130–44.

30. Liu B., Ordonez-Ercan D., Fan Z. et al. Downregulation of erbB3 abrogates erbB2- mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007;120(9):1874–82.

31. O’Regan R.M., Osipo C., Ariazi E. et al. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006;12(7):2255–63.

32. Hotta T., Tanimura H., Yamaue H. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res 1996;66(1):31–5.

33. Shen L.Z., Hua Y.B., Yu X.M. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol 2005;11(7):1060–4.

34. Safa A.R., Roberts S., Agresti M., Fine R.L. Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. Biochem Biophys Res Commun 1994;202(1):606–12.

35. Rao U.S., Fine R.L., Scarborough G.A. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994;48(2):287–92.

36. Chen Y.M., Perng R.P., Yang K.Y. et al. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63(8):605–11.

37. Yang C.H., Cheng A.L., Yeh K.H. et al. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. Cancer 1999;86(3):415–20.